Balamuthia mandrillaris

Morphology

B. mandrillaris is a free-living, heterotrophic amoeba, consisting of a standard complement of organelles surrounded by a three-layered cell wall (thought to be made of cellulose), and with an abnormally large cell nucleus. On average, a Balamuthia trophozoite is about 30 to 120 μm in diameter. The cysts fall around this range, as well.

Life cycle

Balamuthias lifecycle, like the Acanthamoeba, consists of a cystic stage and a non-flagellated trophozoite stage, both of which are infectious, and both of which can be identified in the brain tissue on microscopic examination of brain biopsies performed on infected individuals. The trophozoite is pleomorphic and uninucleated, but binucleated cells are occasionally seen. Cysts are also uninucleated, possessing three walls: an outer thin irregular ectocyst, an inner thick endocyst, and a middle amorphous fibrillar mesocyst.

Pathology

B. mandrillaris is larger than human leukocytes, thus making phagocytosis impossible. Instead, the immune system attempts to contain them at the portal of entry (usually an open wound) by mounting a type IV hypersensitivity reaction. Upon introduction, the amoeba may form a skin lesion, or in some cases, may migrate to the brain, causing a condition known as granulomatous amoebic encephalitis (GAE), which is usually fatal. This granulomatous feature is mostly seen in immunocompetent patients; immunocompromised individuals exhibit a "perivascular cuffing". Balamuthia-induced GAE can cause focal paralysis, seizures, and brainstem symptoms such as facial paralysis, difficulty swallowing, and double vision.

Balamuthia may also cause a variety of non-neurological symptoms, including skin lesions, which can progress to GAE. Patients experiencing this particular syndrome may report a skin lesion (often similar to those caused by MRSA), which does not respond well to antibiotics. The lesion is usually localized and very slow to heal, or fails to heal altogether. In some presentations, this infection may be mistaken for certain forms of skin cancer or cutaneous leishmaniasis. Balamuthia lesions are most often painless.

Culturing and identification

Biopsies of skin lesions, sinuses, lungs, and the brain can detect of B. mandrillaris infection. The amoeba cannot be cultured on an agar plate coated with E. coli because, unlike Naegleria or Acanthamoeba, Balamuthia mandrillaris does not feed on bacteria. Instead, Balamuthia must be cultured on primate hepatocytes or human brain microvascular endothelial cells. Formalin-fixed paraffinized biopsy specimens may indicate Balamuthia trophozoites in the perivascular space. The cysts can be visualized by calcofluor white, which binds to polysaccharides on the cyst wall. Trophozoites appear circular during infection.

Vero cells have been suggested as a possible cheaper and faster alternative to culture the organism. Several types of animal cells have been used in B. mandrillaris culturing including rat glioma cells, human lung cells, and human brain microvascular endothelial cells. These animal cells are added to a specified sterilized growth medium for co culturing with the pathogen. This can also help differentiate between Balamuthia and other protozoa.

Axenic culture methods that are of importance to antiprotozoal drug development have also been reported within the last decade

Treatment

Infection seems to be survivable if treated early. Two individuals, a 5-year-old girl and a 64-year-old man, developed GAE. After diagnosis, they were treated with flucytosine, pentamidine, fluconazole, sulfadiazine, a macrolide antibiotic and trifluoperazine. Both patients recovered. In 2018, an unsuccessful attempt at treatment of a Balamuthia infection after nasal lavage with untreated tap water was reported.

Nitroxoline has shown interesting properties in vitro and might be a possible treatment for this infection. A man treated with nitroxoline at UCSF Medical Center in 2021, following a seizure that was identified to have resulted from CNS invasive Balamuthia infection, survived and recovered from the disease, indicating that nitroxoline might be a promising medication. An opinion article published in the Washington Post in 2025 mentions a pediatric patient who recovered from the infection after being administered nitroxoline.

Organ transplantation

According to a report published in Morbidity and Mortality Weekly Report in September 2010, two confirmed cases of Balamuthia transmission occurred through organ transplantation in December 2009 in Mississippi. Two kidney recipients, a 31-year-old woman and a 27-year-old man, suffered from post-transplant encephalitis due to Balamuthia. The woman died in February 2010 and the man survived with partial paralysis of his right arm. The CDC was notified by a physician on December 14, 2009, about possible transplant transmission in these two patients. Histopathologic testing of donor and recipient tissues confirmed the transmission. Two other patients who received heart and liver transplants from the same donor, but in different hospitals, were placed on preemptive therapy and remain unaffected. A second cluster of transplant-transmitted Balamuthia in Arizona was reported in the same weekly report. Four recipients were identified, two from Arizona (liver and kidney-pancreas), one from California (kidney), and another from Utah (heart). Recipients from Arizona—a 56-year-old male and a 24-year-old male—both succumbed to GAE within a span of 40 days from transplantation. The other two were placed on preemptive therapy after the first two were reported and remain unaffected.

References

References

1. (2009). "A rare but fatal case of granulomatous amebic encephalitis with brain abscess: the first case reported from Turkey". Turkish Neurosurgery.
2. (2019-05-17). "The Epidemiology and Clinical Features of Balamuthia mandrillaris Disease in the United States, 1974 – 2016". Clinical Infectious Diseases.
3. (1990-12-28). "Leptomyxid ameba, a new agent of amebic meningoencephalitis in humans and animals". Journal of Clinical Microbiology.
4. "Balamuthia mandrillaris ameba infection". Centers for Disease Control and Prevention.
5. Frederick L. Schuster. (July 2003). "Environmental Isolation of ''Balamuthia mandrillaris'' Associated with a Case of Amebic Encephalitis". J. Clin. Microbiol..
6. (September 2004). "''Balamuthia mandrillaris'' from soil samples". Microbiology.
7. (2014). "Govinda S. Visvesvara: A Tribute". The Journal of Eukaryotic Microbiology.
8. (2009). "The cyst wall carbohydrate composition of Balamuthia mandrillaris". Parasitology Research.
9. (2015). "''Balamuthia mandrillaris'': Morphology, biology and virulence". Trop. Parasitol..
10. (2011). "Tropical Infectious Diseases:Principles, Pathogens and Practice". Saunders.
11. (2015). "Pathogenesis of amoebic encephalitis: Are the amoebae being credited to an 'inside job' done by the host immune response?". Acta Tropica.
12. (December 1992). "''Acanthamoeba'' meningoencephalitis in a patient with acquired immunodeficiency syndrome". Archives of Pathology & Laboratory Medicine.
13. (Dec 2014). "Granulomatous amoebic encephalitis: ghost response of an immunocompromised host?". J Med Microbiol.
14. (2021). "Balamuthia mandrillaris: An opportunistic, free-living ameba – An updated review". Tropical Parasitology.
15. (March 2001). "''Balamuthia mandrillaris'' infection". J. Med. Microbiol..
16. (2015). "Clinical metagenomic identification of Balamuthia mandrillaris encephalitis and assembly of the draft genome: the continuing case for reference genome sequencing". Genome Medicine.
17. Ferrins L, Buskes MJ, Kapteyn MM, Engels HN, Enos SE, Lu C. (2023). "Identification of novel anti-amoebic pharmacophores from kinase inhibitor chemotypes.". Front Microbiol.
18. Lares-Jiménez LF, Gámez-Gutiérrez RA, Lares-Villa F. (2015). "Novel culture medium for the axenic growth of Balamuthia mandrillaris.". Diagn Microbiol Infect Dis.
19. (15 November 2003). "Successful Treatment of Balamuthia Amoebic Encephalitis: Presentation of 2 Cases". Clinical Infectious Diseases.
20. (December 2018). "Fatal Balamuthia mandrillaris brain infection associated with improper nasal lavage". International Journal of Infectious Diseases.
21. (2018). "Functional Assessment of 2,177 U.S. and International Drugs Identifies the Quinoline Nitroxoline as a Potent Amoebicidal Agent against the Pathogen Balamuthia mandrillaris". mBio.
22. (2023). "Repurposed drug battles 'brain-eating' amoeba". Science.
23. (2023). "Successful Treatment of Balamuthia mandrillaris Granulomatous Amebic Encephalitis with Nitroxoline". Emerging Infectious Diseases.
24. "The Free-Living Bureaucrat". The Washington Post.
25. (17 September 2010). "Balamuthia mandrillaris transmitted through organ transplantation --- Mississippi, 2009.". [[Morbidity and Mortality Weekly Report]].
26. (17 September 2010). "Notes from the field: transplant-transmitted Balamuthia mandrillaris --- Arizona, 2010.". [[Morbidity and Mortality Weekly Report]].